Skip to main content

Table 2 Variables at diagnosis of AML patients with t(8;21) who achieved complete remission and received chemotherapy only and allo-HSCT

From: Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation

Variable

All

Chemotherapy only

Allo-HSCT

P value

Total

88

43

45

Age (years)

36 (14–60)

42 (14–60)

36 (14–54)

0.36

Malesa

47 (53%)

19 (44%)

28 (62%)

0.13

WBC (×109/L)

8.3 (1.3–112)

8.1 (1.3–112)

8.6 (1.2–83)

0.41

Blast cells percentage in the bone marrow (%)

46% (18%–87%)

46% (23%–87%)

48% (18%–83%)

0.82

Platelet count (×109/L)

29 (4–187)

30 (5–187)

28 (4–106)

0.38

Other cytogenetic abnormality than t(8;21)a

54 (64%)

24 (59%)

30 (70%)

0.36

RUNX1-RUNX1T1 transcript level

466% (97%–2545%)

532% (186%–2545%)

422% (97%–933%)

0.31

C-KIT mutationa

30 (34%)

15 (35%)

15 (33%)

1.00

  1. RUNX1-RUNX1T1 Runt-related transcription factor 1-RUNX1 translocation partner 1, C-KIT cellular homolog of the viral oncogene v-KIT receptor tyrosine kinase
  2. aThese values are presented as number of patients followed by percentage in parentheses; other values are presented as median followed by a range in parentheses